ALLURION TECHN. O.N. Aktie

The FDA has approved the Allurion Smart Capsule gastric balloon system for weight loss, after which Allurion’s stock rose by around 40%. The swallowable capsule is introduced in a 15‑minute office procedure without surgery or anesthesia, stays in the stomach for about four months and is then naturally excreted. Allurion sees access to roughly 80 million U.S. adults with a BMI of 30–40 and cites over 200,000 patients treated outside the U.S., as well as studies showing mean weight losses of about 14% (one cycle) and over 20% (two cycles). » Plus sur de.investing.com

A peer‑reviewed case‑control study of 1,143 patients found that the Allurion Smart Capsule combined with lifestyle intervention produced an average 20% weight loss after 36 weeks, comparable to bariatric procedures and high‑dose GLP‑1 therapies. Participants experienced greater fat loss and reduced visceral fat measures without a negative impact on muscle mass. The capsule is swallowed on an outpatient basis and expelled after four months; in the US it remains an investigational product. Allurion is, however, facing high debt and strong cash burn, reported a revenue decline in Q3 2025 while reducing its operating loss, and has signed a distribution partnership with ProSurg Medical for Brazil. » Plus sur de.investing.com

Allurion Technologies reports that Milena Alberti-Perez resigned from the board of directors and as chair of the audit committee effective September 30, 2025. Her resignation is not due to disagreements with management or the board; she intends to focus on activities in the media sector. The board will shrink from nine to eight members and is reviewing a successor for the audit committee chair. The company also reported a significant revenue decline in Q2 2025 and a strategic realignment; analysts, including TD Cowen, nevertheless maintain a buy rating with a $6.00 target. » Plus sur de.investing.com